Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 2OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 1Recurrence 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Osteosarcoma 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Hodgkin Disease 1Alveolar Childhood Rhabdomyosarcoma 1

Interventions

Filgrastim 13Cyclophosphamide 13Etoposide 12Doxorubicin 11fludarabine phosphate 10Vincristine 10Cyclosporine 10Peripheral Blood Stem Cell Transplantation 9Radiotherapy 8Prednisone 8Vinblastine 6Tacrolimus 6Rituximab 6Methotrexate 6Gemcitabine 6Bleomycin 6tanespimycin 5Vorinostat 5Ipilimumab 5Bortezomib 5temsirolimus 4Sirolimus 4Nivolumab 4Mycophenolic Acid 4Melphalan 4Magnetic Resonance Spectroscopy 4Ifosfamide 4Dacarbazine 4Cytarabine 4CTLA-4 Antigen 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Hodgkin Disease × indolepropanol phosphate × Clear all
NCT00381940 2021-03-24

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

National Cancer Institute (NCI)

Phase 2 Completed
26 enrolled 14 charts
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡